An interventional study of VascuTherm5 vascular compression device in Chemotherapy-induced Peripheral Neuropathy and Plasma Cell Myeloma, sponsored by Wake Forest University Health Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Multiple Myeloma by Wake Forest University Health Sciences — 5 open to participants now, 7 under way, none of them phase 3. Multiple Myeloma · Wake Forest University Health Sciences.
Among the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 with no phase, and was the 14th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →5 of the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 40–49 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 30+ · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18–120
By country, each count listing its studies:
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9
First in 2001; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 18 across the 17 interventional studies, 54 across the 7 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
2 of the studies in Multiple Myeloma by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT06870760Wake Forest University Health SciencesPre-malignant States to Hematologic Malignancies in Firefighters | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. Cryocompression is a treatment where a glove and a boot are worn to cool down the skin. This cooling treatment is safe and does not interfere with chemotherapy treatment. Daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.
PRIMARY OBJECTIVES:
I. To assess the feasibility of daily cryocompression therapy in multiple myeloma patients with bortezomib-induced peripheral neuropathy (BIPN).
SECONDARY OBJECTIVES:
I. To examine the change in patient-reported assessment of neuropathy based on the sensory, motor and autonomic neuropathy scores on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Cancer-Induced Peripheral Neuropathy (CIPN20) (patient-reported outcome [PRO]) from baseline to 4 and 8 weeks after the start of cryocompression therapy.
II. To examine the change in physician graded assessment of peripheral neuropathy by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 criteria from baseline to 4 and 8 weeks after the start of cryocompression therapy.
III. To assess the effect on sensory and motor nerve function via nerve conduction study (NCS) (e.g. conduction velocity, latency, and amplitude) and neuro-ultrasound after 8 weeks of daily cryocompression therapy.
EXPLORATORY OBJECTIVES:
I. To explore the effect of 8 weeks of cryocompression on changes in digital artery perfusion as measured by ultrasound (US).
II. To examine the associations among the peripheral nerve assessment measures (nerve conduction and peripheral nerve US) with the patient reported outcomes (EORTC QLQ-CIPN20, PRO-CTCAE) at baseline, week 4, week 8, and for the change from baseline to week 8.
OUTLINE:
Patients undergo home cryocompression therapy treatments on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
After completion of cryocompression therapy, patients are followed up at 30 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort 1: Patients with clinically documented CTCAE grade greater than or equal 2 neuropathy.
Cohort 2: Patients with clinically documented CTCAE grade 1-2 neuropathy.
Cohort 1: Patients who have previously received a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.
Cohort 2: Patients who are currently receiving a bortezomib-containing regimen and have clinically documented neuropathy that is attributed to the bortezomib containing regimen.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
Device: VascuTherm5 vascular compression device
VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
Device: VascuTherm5 vascular compression device
VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
Feasibility - Ability to Complete Daily 30-minute Cryocompression Treatments
The primary outcome measure will be feasibility of daily 30-minute cryocompression treatments with a target of 60% compliance. Compliance will be measured with patient diaries. Only periods for which diaries exist will be evaluated. Compliance is defined as completion of 60% of prescribed treatment days. Completion of at least 25 of 30 minutes on each day will be considered completion of therapy on the prescribed day. Analyses will be primarily descriptive to estimate variances and effect sizes for future work. The proportion of compliance and its 95% confidence interval will be calculated for each cohort.
Time frame: Baseline up to 8 weeks of cryocompression therapy
EORTC QLQ-CIPN20 Questionnaire
Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. Patient-reported assessment of neuropathy based on 19 questions from components of sensory, motor, and autonomic neuropathic. Question responses are (scale of 1 to 4) 1 being "not at all" and 4 being "very much." The total EORTC score (calculated as the average of the component responses) (range 1-4) and then converted to a 100 point scale (range 0-100) with higher scores having more severe symptoms or greater functional limitation. EORTC QLQ-CIPN20 (PRO) will be done at baseline, and at 4 and 8 weeks of cryocompression therapy.
Time frame: Baseline, 4 weeks, 8 weeks
NCI-CTCAE v5.0 Severity Grade Changes
Physician graded assessment of peripheral neuropathy as measured by NCI-CTCAE v5.0 criteria. The CTCAE displays Grades 1 through 5 (1 = mild, 5 = death)
Time frame: Baseline, 4 weeks, 8 weeks
Change in Motor Nerve Function (Tibial Amplitude) From Baseline to 8 Weeks
Change in tibial motor response from baseline to 8 weeks will include tibial amplitude (mV)
Time frame: Baseline, 8 weeks
Change in Motor Nerve Function (Latency) From Baseline to 8 Weeks
Change in Tibial motor response from baseline to 8 weeks will include latency (ms)
Time frame: Baseline, 8 weeks
Change in Motor Nerve Function (Conduction Velocity) From Baseline to 8 Weeks
Change in tibial motor response from baseline to 8 weeks will include conduction velocity (m/sec).
Time frame: Baseline, 8 weeks
Sensory Response Evaluability at Baseline and 8 Weeks
Sural sensory response (collected as yes/no) measured on both the left and right ankles at baseline and 8 weeks for amplitude, onset latency, and peak latency. Reported are the number with sural sensory response measured (yes).
Time frame: Baseline, 8 weeks
| Milestone | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Started | 12 | 6 |
| Completed | 9 | 5 |
| Not completed | 3 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
The primary outcome measure will be feasibility of daily 30-minute cryocompression treatments with a target of 60% compliance. Compliance will be measured with patient diaries. Only periods for which diaries exist will be evaluated. Compliance is defined as completion of 60% of prescribed treatment days. Completion of at least 25 of 30 minutes on each day will be considered completion of therapy on the prescribed day. Analyses will be primarily descriptive to estimate variances and effect sizes for future work. The proportion of compliance and its 95% confidence interval will be calculated for each cohort.
| percentage of compliant participants | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Feasibility - Ability to Complete Daily 30-minute Cryocompression Treatments | 100 (100 to 100) | 66.7 (4.3 to 77.7) |
Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. Patient-reported assessment of neuropathy based on 19 questions from components of sensory, motor, and autonomic neuropathic. Question responses are (scale of 1 to 4) 1 being "not at all" and 4 being "very much." The total EORTC score (calculated as the average of the component responses) (range 1-4) and then converted to a 100 point scale (range 0-100) with higher scores having more severe symptoms or greater functional limitation. EORTC QLQ-CIPN20 (PRO) will be done at baseline, and at 4 and 8 weeks of cryocompression therapy.
| score on a scale | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Baseline | 39 ± 17 | 30 ± 8 |
| 4 weeks | 27 ± 11 | 25 ± 12 |
| 8 weeks | 28 ± 15 | 22 ± 7 |
Physician graded assessment of peripheral neuropathy as measured by NCI-CTCAE v5.0 criteria. The CTCAE displays Grades 1 through 5 (1 = mild, 5 = death)
| participants | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Baseline - Grade 1 Peripheral Neuropathy | 1 | 1 |
| Baseline - Grade 2 Peripheral Neuropathy | 8 | 5 |
| Baseline - Grade 3 Peripheral Neuropathy | 3 | 0 |
| Week 4 - Grade 1 Peripheral Neuropathy | 1 | 0 |
| Week 4 - Grade 2 Peripheral Neuropathy | 7 | 5 |
| Week 4 - Grade 3 Peripheral Neuropathy | 0 | 0 |
| Week 8 - Grade 1 Peripheral Neuropathy | 2 | 2 |
| Week 8 - Grade 2 Peripheral Neuropathy | 5 | 4 |
| Week 8 - Grade 3 Peripheral Neuropathy | 3 | 0 |
Change in tibial motor response from baseline to 8 weeks will include tibial amplitude (mV)
| mV | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Right Median Wrist | -0.6 ± 2.3 | 1.0 ± 1.9 |
| Left Median Wrist | -0.2 ± 2.6 | -0.5 ± 2.1 |
| Right Median Elbow | -0.8 ± 2.0 | 1.0 ± 2.1 |
| Left Median Elbow | 0 ± 2.0 | -0.1 ± 1.6 |
| Right Tibial Ankle | 0.4 ± 1.4 | -1.0 ± 1.7 |
| Left Tibial Ankle | 0.8 ± 1.0 | -0.3 ± 2.1 |
Change in Tibial motor response from baseline to 8 weeks will include latency (ms)
| ms | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Right Median Wrist | 0.1 ± 0.4 | 0.0 ± 0.2 |
| Left Median Wrist | 0.1 ± 0.3 | -0.1 ± 0.3 |
| Right Median Elbow | 0.1 ± 0.4 | 0.0 ± 0.4 |
| Left Median Elbow | 0.0 ± 0.5 | -0.1 ± 0.4 |
| Right Tibial Ankle | -0.1 ± 0.5 | 0.1 ± 0.3 |
| Left Tibial Ankle | 0.3 ± 0.5 | -0.1 ± 0.2 |
Change in tibial motor response from baseline to 8 weeks will include conduction velocity (m/sec).
| m/s | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Right Median Elbow | 0.2 ± 2.8 | -1.0 ± 1.3 |
| Left Median Elbow | 0.2 ± 4.0 | -0.3 ± 3.0 |
Sural sensory response (collected as yes/no) measured on both the left and right ankles at baseline and 8 weeks for amplitude, onset latency, and peak latency. Reported are the number with sural sensory response measured (yes).
| number patients | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| Baseline - Amplitude response - Right Sural ANKLE (Calf) | 2 | 2 |
| Baseline - Amplitude response - Left Sural ANKLE (Calf) | 1 | 2 |
| 8 weeks - Amplitude response - Right Sural ANKLE (Calf) | 2 | 2 |
| 8 Weeks - Amplitude response - Left Sural ANKLE (Calf) | 1 | 3 |
| Baseline - Onset Latency response - Right Sural ANKLE (Calf) | 2 | 2 |
| Baseline - Onset Latency response - Left Sural ANKLE (Calf) | 1 | 2 |
| 8 weeks - Onset Latency response - Right Sural ANKLE (Calf) | 2 | 2 |
| 8 weeks - Onset Latency response - Left Sural ANKLE (Calf) | 1 | 3 |
| Baseline - Peak Latency response - Right Sural ANKLE (Calf) | 2 | 2 |
| Baseline - Peak Latency response - Left Sural ANKLE (Calf) | 1 | 2 |
| 8 weeks - Peak Latency response - Right Sural ANKLE (Calf) | 2 | 2 |
| 8 weeks - Peak Latency response - Left Sural ANKLE (Calf) | 1 | 3 |
Collected over Adverse events were collected at initiation of treatment (day 0, week 1), at week 4, and week 8 visits. One enrolled participant was never treated and no adverse event data was collected on that participant, but that participant was followed for all cause mortality.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Grade 2-3 Established Neuropathy | 0/12 (0%) | 0/11 (0%) | 9/11 (81.8%) |
| Grade 1-2 New-onset Neuropathy | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy |
|---|---|---|
| ParesthesiaNervous system disorders | 6/11 | 1/6 |
| Peripheral sensory neuropathyNervous system disorders | 5/11 | 1/6 |
| PainGeneral disorders | 3/11 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/11 | 1/6 |
| ArthritisMusculoskeletal and connective tissue disorders | 2/11 | 0/6 |
| Muscle crampMusculoskeletal and connective tissue disorders | 2/11 | 1/6 |
| DysesthesiaNervous system disorders | 2/11 | 0/6 |
| InsomniaPsychiatric disorders | 1/11 | 0/6 |
| PruritusSkin and subcutaneous tissue disorders | 1/11 | 0/6 |
| Age, Categorical(Participants) | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 8 |
| >=65 years | 8 | 2 | 10 |
| Sex: Female, Male(Participants) | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 7 | 4 | 11 |
| Race (NIH/OMB)(Participants) | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 9 | 5 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Grade 2-3 Established Neuropathy | Grade 1-2 New-onset Neuropathy | Total |
|---|---|---|---|
| United States | 12 | 6 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2019 to primary completion in Feb 2023, 39 months.
Results were first posted in Oct 2026, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →